AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02870972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01513330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Mio
Description: Ostomy product - 1 piece closed bag
Study NCT01513330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Ostomy product 1 piece closed bags. Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima.
Study NCT01515696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gastrografin
Description: Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
Study NCT01515696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
Study NCT02253576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inhaled 7% hypertonic saline
Description: Three consecutive doses of 4 ml of 7% hypertonic saline added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
Study NCT02253576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inhaled nebulized normal saline
Description: Three consecutive doses of 4 ml of 0.9% NaCl added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
Study NCT02092532 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rescue Intravitreal Aflibercept Injection
Description: Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.
Study NCT02092532 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rescue Therapy with PDT, Laser or Intravitreal Steroids
Description: Starting at Month 3, patients can receive non-anti VEGF rescue therapy (ie: PDT, laser, intravitreal steroids) if the pre-defined criteria are met.
Study NCT02523547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavir
Description: 0.5mg/day
Study NCT02523547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baraclude
Description: 0.5mg/day
Study NCT01403870 — intervention group
Intervention type: OTHER
Intervention: Physical Therapy
Description: The physician will complete a physical exam as well as analyze a completed CERSR scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
Study NCT03124693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow DCI pulse oximeter sensor
Study NCT00073398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug: Hyperacute Lung Cancer Cell Vaccine
Description: At dose levels I IV the vaccine cells will be injected intradermally every four weeks for four cycles. Dosage will vary from a total of 3 x 106 to 100 x 106 HyperAcute -Lung Cancer Vaccine cells administered per vaccination cycle. At dose level V patients will receive injections of the HyperAcute -Lung Cancer Vaccine cells to include one (1) initial priming vaccine dose of 500 x 106 cells followed by seven (7) booster vaccine cell doses of 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks. In Phase II, patients will receive 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks for a total of 8 doses (4 months).
Study NCT03144544 — intervention group
Intervention type: PROCEDURE
Intervention: Pediatric surgical procedures
Description: Eligible surgical procedures were identified using Canadian Classification of Health Interventions (CCI) therapeutic intervention codes.
Study NCT00915083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: 40mg/m\^2 5 minute IV infusion for 3 consecutive days (21 day cycle)
Study NCT00360477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Floseal
Description: Bioglue that seals the kidney
Study NCT00360477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cope Loop
Description: Nephrostomy tube for fluid drainage from the kidney
Study NCT00360477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial Stitch
Description: Stitch that closes the kidney
Study NCT01179776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilomedin
Description: Ilomedin
Study NCT01179776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: i.v saline
Study NCT01179776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilomedin
Study NCT01179776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilomedin and standard low dose treatment
Study NCT01578213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: * Capsules, hard 50 or 100 mg/Film-coated Tablets 100 or 400 mg~* Total dosage per day: 800 mg~* Oral use
Study NCT01921647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Study NCT01921647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Study NCT01921647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Study NCT01921647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Study NCT01921647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Study NCT01921647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin
Study NCT03043430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 100 MG/ML
Description: Administer ketamine via mucosal atomization device
Study NCT03043430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam 5 MG/ML
Description: Administer midazolam via mucosal atomization device
Study NCT04361812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS632
Description: Subcutaneous injection of HS632
Study NCT04361812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab (Xolair®)
Description: Subcutaneous injection of Omalizumab Xolair®)
Study NCT02339597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automatic Positive Airway Pressure (APAP) initiation
Study NCT01535001 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular training (NEMEX-TJR)
Description: 60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Study NCT01535001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.~Information will be given in a leaflet.
Study NCT01535001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1 g x 4/day
Study NCT01535001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Burana
Description: 400 mg x 3/day for three weeks
Study NCT01535001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 20mg x 1/day for three weeks
Study NCT01535001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: For participants with a BMI equal to or >25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
Study NCT01535001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden.
Study NCT01535001 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insoles
Description: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes.
Study NCT01907932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VScan Ultrasound (GE Healthcare, USA)
Description: VScan Ultrasound used to determine spleen size and the other qualities described in the arm description.
Study NCT05021445 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: plates based exercises
Description: 12 elderly participants receive intervention protocol of Plates- based exercises program total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
Study NCT05021445 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: conventional exercises
Description: 12 elderly participants,intervention protocol of Conventional balance training exercises,total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
Study NCT01013961 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: alemtuzumab
Description: Given IV
Study NCT01013961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given IV
Study NCT01013961 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Given IV
Study NCT01013961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT04548986 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aktiia.product
Description: The participants wear Aktiia.bracelet for the duration of the cardiac rehabilitation program. The device is initialized once per week.
Study NCT00778232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin tablets 800 mg
Study NCT00778232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin tablets 800 mg
Study NCT02634047 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional technique
Description: transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
Study NCT02634047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: videolaryngoscope technique
Description: transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
Study NCT03785106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
Description: Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
Study NCT03785106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
Description: Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
Study NCT00882115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli sprout extract (BSE)
Description: BSE will be ingested by drinking a liquid formula containing 1.25 g BSE in a volume equaling 1 cup daily for 4 consecutive days in the BSE intervention phase.
Study NCT00981708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Dexamethasone and Cyclophosphamide
Description: Lenalidomide capsules on days 1 to 21. the dose starts at 5 mg/day up to 25 mg/day.~Dexamethasone tablets on days 1 to 4. Dose 20 mg per day.~Cyclophosphamide tablets on days 1 to 10. The dose starts at 50 mg per day up to 100 mg per day.~The cycle is to be repeated every 28 days (4 weeks)
Study NCT04250779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CapMedic smart inhaler device
Description: The CapMedic device provides active coaching to promote correct and regular use of MDI.
Study NCT04250779 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Video-based guidance
Description: Patients are shown a video of how to use inhalers correctly and any questions are answered by the clinician. They are also encouraged to use inhalers regularly and correctly at home.
Study NCT04789343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Root canal treatment
Description: The patient usually takes anaesthesia before treatment and access cavity was prepared on the tooth and root canal removed and instrumented and obturated. However, in the present study, previously done root canal was retreated. Usually no anaesthesia was used because all root canals were done before. So just instrumentation and obturation was done.
Study NCT00425607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Lonafarnib will be taken orally, twice per day, by all patients enrolled on this study. The drug is supplied to patients in capsule form, and for patients who are unable to swallow pills, the drug may be dissolved into solution. Every patient will start lonafarnib therapy at a dose of 115mg/kg. The study allows for patients to receive a dose escalation (up to 150mg/kg) if the drug is being well-tolerated. Every patient enrolled on this study will undergo two years of lonafarnib therapy.
Study NCT02901769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: two fMRI paradigms, emotional prosody recognition and decision making
Study NCT02901769 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fMRI
Description: two fMRI paradigms, emotional prosody recognition and decision making
Study NCT03673995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol+L-tyrosine
Description: PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients underwent, before starting the therapy, after 3 months and 6 months, hormonal, hirsutism and ovulation assesment.
Study NCT01202799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% w/w diclofenac sodium topical gel
Description: 2% w/w diclofenac sodium topical gel
Study NCT01202799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5% w/w diclofenac sodium topical solution
Description: 1.5% w/w diclofenac sodium topical solution
Study NCT01202799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 75 mg diclofenac sodium delayed release tablet
Description: 75 mg diclofenac sodium delayed release tablet
Study NCT02937649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy using 48-Fr bougie
Description: After gastric mobilization, the 48-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
Study NCT02937649 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy using standard care bougie
Description: After gastric mobilization, the standard care bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
Study NCT02743897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier
Description: Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
Study NCT02743897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavyret
Description: Mavyret (glecaprevir 100 mg and pibrentasvir 40 mg) is taken by mouth for 8 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
Study NCT00371176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist
Study NCT00371176 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exposure therapy
Description: A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist
Study NCT03247881 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nut Free Diet
Description: Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
Study NCT03247881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Added Mixed Nuts Diet
Description: Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
Study NCT03743844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion-focused psychoeducation group
Description: Attending six 2-hour weekly group-based psychoeducation sessions and participating in mindfulness, meditation, and acceptance-based experiential exercises
Study NCT00564291 — intervention group
Intervention type: OTHER
Intervention: Examination with an OCT device
Study NCT00895934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00895934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: Given intravenously (IV)
Study NCT00895934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given IV or subcutaneously (SC)
Study NCT02534519 — intervention group
Intervention type: OTHER
Intervention: Whole Genome Sequencing (WGS)
Description: There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.
Study NCT05447026 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, the sites in the control group received only saline irrigation for 1 min.
Study NCT05447026 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial photodynamic therapy (aPDT) group
Description: Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, aPDT group received additional application of a diode laser with a wavelength of 810 nm and a power rating of 200 mW (continuous mode). Indocyanine-green (ICG) as a photosensitizer at a concentration of 1 mg/ml was applied at the surgical site on both the buccal and the lingual sides of the flaps. Irradiation was performed in non-contact mode in a constant distance of 1 mm during 30 s per site
Study NCT05447026 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED photobiomodulation group
Description: Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, irradiation was carried out with a LED device with a wavelength of 626 nm in the near-infrared region at a dose of 20 mw/cm2 for 20 min with a total energy of 222 J
Study NCT05447026 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topical ozone group
Description: Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, topical ozone group received ozone application with an ozone generator at 80% concentration using probe #3 for 30 s per site
Study NCT00500253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: exhaled nitric oxide measurement
Description: exhaled nitric oxide measurement